Loading organizations...
Timefolio Capital is an investment firm providing venture and growth capital to high-potential companies. It applies a value investing approach, targeting businesses with strong technological capabilities and significant growth prospects across venture and SME sectors. The firm identifies and nurtures innovative enterprises, offering crucial financial partnership to support their sustainable development and long-term value creation.
Established in 2015, Timefolio Capital operates as the corporate venture arm of Timefolio Asset Management. Its formation was spearheaded by co-CEOs Hwang Sung-hwan and Kim Hong-ki, who sought to extend their investment philosophy into fostering innovation and economic growth. This expansion reflected an insight that deploying capital in promising early-stage and growing companies could yield mutual prosperity.
Timefolio Capital serves promising venture, small, and medium-sized enterprises seeking investment for growth and innovation. Its core mission, rooted in mutual prosperity, strives to enrich the nation through technological advancement and its citizens through astute financial investments. The firm aims to be a dedicated financial partner, empowering investee companies to achieve full potential and contribute to broader economic prosperity.
Timefolio Capital has 1 tracked investment across 1 company. The latest tracked deal is $75.0M Series C in Accent Therapeutics in January 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2024 | Accent Therapeutics | $75.0M Series C | — | Atlas Venture, F Prime Capital, Leaps BY Bayer, Nextech Invest, The Column Group, AbbVie Ventures, Bristol Myers Squibb, Droia Ventures, EcoR1 Capital, GV, Johnson & Johnson Innovation, Naveen Krishnan, Mirae Asset Venture Investment, The Mark Foundation For Cancer Research |